Lymph Node Staging in Lung Cancer Using [¹⁸F]FDG-PET

Abstract

Background: Mediastinal lymph node staging is essential to determine treatment options in patients with NSCLC. Positron emission tomography (PET) detects increased glucose uptake in malignant tissue using the glucose analogue 2-[¹⁸F]fluoro-2-deoxy-D-glucose (FDG). Patients and Methods: In the present study were evaluated 155 patients with focal pulmonary tumors who underwent both preoperative computed tomography (CT) and FDG-PET scanning (116 malignant and 39 benign lesions). Results: Findings in 155 patients included 116 malignant and 39 benign lesions. For N-staging, FDG-PET showed a sensitivity of 88 %, a specificity of 91 %, and an accuracy of 89 %. Corresponding figures for CT were 77 %, 76 %, and 77 %, respectively. Conclusions: FDG-PET is an effective, noninvasive method for staging thoracic lymph nodes in patients with lung cancer and is superior to CT scanning in the assessment of hilar and mediastinal nodal metastases. With regard to operability, FDG-PET could differentiate reliable between patients with N1/N2 disease and those with unresectable N3 disease.

Lung cancer - lymph node staging - FDG-PET

References

• 1 Mountain C F. Revisions in the international system for staging lung cancer.  Chest. 1997;  111 1710-1717
• 2 Wittekind C H, Wagner (eds) G. UICC TNM-Klassifikation maligner Tumoren. Berlin, Heidelberg, New York; Springer 1997
• 3 Drings P, Vogt-Moykopf I. Thoraxtumoren. Heidelberg, New York; Springer 1998
• 4 Glazer G M, Gross B H, Quint L E, Francis I R, Bookstein F L, Orringer M B. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping.  Am J Roentgenol. 1985;  144 261-265
• 5 McLoud T C, Bourgouin P M, Greenberg R W, Kosiuk J P, Templeton P A, Shepard J A. et al . Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.  Radiology. 1992;  182 319-323
• 6 Dales R E, Stark R M, Raman S. Computed tomography to stage lung cancer. Approaching a controversy using meta-analysis.  Am Rev Respir Dis. 1990;  141 1096-1101
• 7 Gallagher B M, Fowler J S, Gutterson N I, MacGregor R R, Wan C N, Wolf A P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18 F] 2-deoxy-2-fluoro-D-glucose.  J Nucl Med. 1978;  19 1154-1161
• 8 Schmidlin P. Iterative algorithms for emission tomography [in German].  Nuklearmedizin. 1990;  3 155-158
• 9 Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A. et al . A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.  N Engl J Med. 1994;  330 153-158
• 10 McKenna Jr R J, Libshitz H I, Mountain C E, McMurtrey M J. Roentgenographic evaluation of mediastinal nodes for preoperative assessment in lung cancer.  Chest. 1985;  88 206-210
• 11 Staples C A, Muller N L, Miller R R, Evans K G, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy.  Radiology. 1988;  167 367-372
• 12 Kauczor H U, Kreitner K F. Contrast-enhanced MRI of the lung.  Eur J Radiol. 2000;  34 196-207
• 13 [No authors listed]. Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society.  Am J Respir Crit Care Med. 1997;  156 320-332
• 14 Luke W P, Pearson F G, Todd T R, Patterson G A, Cooper J D. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung.  J Thorac Cardiovasc Surg. 1986;  91 53-56
• 15 De Leyn P, Vansteenkiste J, Cuypers P, Deneffe G, Van Raemdonck D, Coosemans W. et al . Role of cervical mediastinoscopy in staging of non-small-cell lung cancer without enlarged mediastinal lymph nodes on CT scan.  Eur J Cardiothorac Surg. 1997;  12 706-712
• 16 Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske S N. Lymph node staging in non-small cell lung cancer: evaluation by [18 F]FDG positron emission tomography (PET).  Thorax. 1997;  52 438-441
• 17 Kalff V, Hicks R J, MacManus M P, Binns D S, McKenzie A F, Ware R E. et al . clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.  J Clin Oncol. 2001;  19 111-118
• 18 Liewald F, Grosse S, Storck M, Guhlmann A, Halter G, Reske S. et al . How useful is positron emission tomography for lymph node staging in non-small-cell lung cancer?.  Thorac Cardiovasc Surg. 2000;  48 93-96
• 19 Scott W J, Schwabe J L, Gupta N C, Dewan N A, Reeb S D, Sugimoto J T. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18 F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group.  Ann Thorac Surg. 1994;  58 698-703
• 20 Shon I H, O'Doherty M J, Maisey M N. Positron emission tomography in lung cancer.  Semin Nucl Med. 2002;  32 240-271
• 21 Vansteenkiste J F, Stroobants S G, De Leyn P R, Dupont P J, Bogaert J, Maes A. et al . Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.  J Clin Oncol. 1998;  16 2142-2149
• 22 Pieterman R M, van Putten J W, Meuzelaar J J, Mooyaart E L, Vaalburg W, Koeter G H. et al . Preoperative staging of non-small-cell lung cancer with positron-emission tomography.  N Engl J Med. 2000;  343 254-261
• 23 Patz Jr E F, Lowe V J, Goodman P C, Herndon J. Thoracic nodal staging with PET imaging with 18 FDG in patients with bronchogenic carcinoma.  Chest. 1995;  108 1617-1621
• 24 Berlangieri S U, Scott A M, Knight S R, Fitt G J, Hennessy O F, Tochon-Danguy H J. et al . F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.  Eur J Cardiothorac Surg. 1999;  16 (Suppl 1) S25-30
• 25 Gupta N C, Graeber G M, Bishop H A. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (> 3 cm) lymph node lesions.  Chest. 2000;  117 773-778
• 26 Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach K W, Schicha H. Cost-effectiveness of FDG-PET for the management of potentially operable non-small-cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.  Eur J Nucl Med. 2000;  27 1598-1609
• 27 Lardinois D, Weder W, Hany T F, Kamel E M, Korom S, Seifert B, von Schulthess G K, Steinert H C. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.  N Engl J Med. 2003;  348 2500-2507